Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

Clinical Pharmacology and Therapeutics
M-S WenY-T Chen

Abstract

Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose. We conducted a prospective study in which warfarin dose was prescribed based on CYP2C9 and VKORC1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR > 4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients' maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R(2) of 0.62). This study demonstrated that pharmacogenetics-based dosing could improve time to stable, therapeutic INR, reduce adverse events, and achieve high sensitivity.

References

Nov 1, 1985·The Journal of Clinical Investigation·R Wallin, L F Martin
Oct 1, 1995·Chest·M N LevineJ Hirsh
Oct 1, 1995·Chest·A LaupacisA Jacobson
Sep 1, 1993·The American Journal of Medicine·C S Landefeld, R J Beyth
Aug 1, 1996·Pharmacogenetics·T H Sullivan-KloseJ A Goldstein
Nov 14, 1997·Pharmacogenetics·K NasuT Ishizaki
Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Jan 1, 1994·Journal of Thrombosis and Thrombolysis·A L GulløvP Petersen
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R LoebsteinD Ezra
Aug 29, 2001·Clinical Pharmacokinetics·H Takahashi, H Echizen
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mitchell K HigashiAllan E Rettie
Oct 31, 2002·Advanced Drug Delivery Reviews·Hong-Guang XieC Michael Stein
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Harumi TakahashiHirotoshi Echizen
Sep 17, 2004·Clinical Pharmacology and Therapeutics·Feng ZhaoSoo Chin Lee
Apr 21, 2005·Thrombosis and Haemostasis·Deepak VooraBrian F Gage
May 11, 2005·The Pharmacogenomics Journal·M WadeliusP Deloukas
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Sep 15, 2005·Clinical Medicine & Research·Michael A HillmanJames K Burmester
Jul 19, 2006·Pharmacogenetics and Genomics·Elizabeth A SconceFarhad Kamali
Aug 8, 2006·Clinical Pharmacology and Therapeutics·Kyoko ObayashiRyuya Horiuchi
Oct 19, 2006·Human Genetics·Mia WadeliusPanos Deloukas
Dec 13, 2006·Thrombosis Research·Tong Yin, Toshiyuki Miyata
Mar 28, 2007·Blood·Eric A MillicanBrian F Gage

❮ Previous
Next ❯

Citations

Jun 19, 2013·European Journal of Clinical Pharmacology·Tudor Radu PopAnca Dana Buzoianu
Mar 24, 2009·Journal of General Internal Medicine·Kirsten Neudoerffer KangelarisJeffrey A Tice
May 10, 2013·Journal of Human Genetics·Ming Ta Michael Lee, Teri E Klein
Nov 27, 2009·Pharmacogenetics and Genomics·Ryan P OwenRuss B Altman
Aug 19, 2009·Annual Review of Medicine·Farhad Kamali, Hilary Wynne
Oct 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Harumi Takahashi
Mar 18, 2009·Pharmacogenomics·Hui-Hung WangYuan-Tsong Chen
Dec 5, 2009·Pharmacogenomics·M T Michael LeeYuan-Tsong Chen
Nov 7, 2009·Pharmacogenomics·Maha KadafourJaekyu Shin
Oct 22, 2009·Pharmacogenomics·Ming Ta Michael LeeYuan-Tsong Chen
Feb 23, 2010·Personalized Medicine·Haifeng M WuMark W Wurster
Mar 27, 2010·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Harumi Takahashi
Apr 5, 2011·Cleveland Clinic Journal of Medicine·Joseph P KitzmillerWolfgang Sadee
Nov 11, 2008·Heart Failure Reviews·Ingrid GlurichMichael D Caldwell
Jun 13, 2014·Thrombosis and Haemostasis·E Jiménez-VaroM Á Calleja-Hernández
Aug 30, 2008·Pharmacotherapy·Nita A Limdi, David L Veenstra
Jul 17, 2008·Journal of Thrombosis and Haemostasis : JTH·S M ThackerB F Gage
Jan 31, 2009·Journal of Clinical Pharmacology·Myong-Jin KimLawrence J Lesko
Oct 26, 2011·British Journal of Clinical Pharmacology·May P S Lam, Bernard M Y Cheung
Aug 7, 2012·Journal of Cellular and Molecular Medicine·Anca D BuzoianuSorin Crişan
Mar 14, 2013·Cardiovascular Therapeutics·Helen M ParryChim C Lang
Sep 5, 2014·Journal of Clinical Pharmacology·Xi LiWei Zhang
Aug 8, 2013·British Journal of Clinical Pharmacology·Talitha I VerhoefAnke-Hilse Maitland-van der Zee
Nov 12, 2015·Pharmacogenomics·Mohamed Subhan AnwarChim C Lang
Aug 13, 2015·Pharmacogenomics·Esteban J ParraGuilherme Suarez-Kurtz
Jan 15, 2011·Expert Opinion on Pharmacotherapy·Joyce Hs You
Oct 9, 2015·Research in Cardiovascular Medicine·Avisa TabibBehzad Poopak
Jun 9, 2014·Thrombosis Research·Tejasvita GaikwadShrimati Shetty
Jan 29, 2011·Journal of the American College of Cardiology·Brian S FinkelmanStephen E Kimmel
Jan 15, 2010·Clinical Pharmacology and Therapeutics·L H CavallariJ A Johnson
Jun 15, 2016·Indian Journal of Pharmacology·Meiqin LinHongtao Song
Nov 20, 2012·Blood Cells, Molecules & Diseases·Anca Dana BuzoianuSorin Crişan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.